Covid-19 roundup: J&J to apply for booster authorization this week as adcomms are set; BioNTech CEO Ugur Sahin predicts need for new vaccine formulation

Nicole DeFeudis

Editor

Two weeks after releasing new data showing its Covid-19 booster shot bumped protection against moderate to severe disease up to 75% worldwide, J&J is reportedly …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Covid-19 roundup: J&J to apply for booster authorization this week as adcomms are set; BioNTech CEO Ugur Sahin predicts need for new vaccine formulation

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Pfizer wants in on Summit’s goal to beat Keytruda via ADC combos

Post-Hoc: Pharma CEOs' alternative reality with Trump

Sanofi, Teva bolster case for IBD drug with Phase 2 data, despite potential competition

FDA approves first drug to treat ultra-rare lipid storage disease

CBER's deputy director departs as staff shakeup continues

How AI can address ongoing challenges in the life sciences industry

Covid-19 roundup: J&J to ap­ply for boost­er au­tho­riza­tion this week as ad­comms are set; BioN­Tech CEO Ugur Sahin pre­dicts need for new vac­cine for­mu­la­tion

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Covid-19 roundup: J&J to apply for booster authorization this week as adcomms are set; BioNTech CEO Ugur Sahin predicts need for new vaccine formulation